Evidence & regulatory context
- Mechanism
- ChEMBL NOT QUERIED as a drug entity: 'anti-CXCL14 neutralising antibody' is a research-reagent class description, not a named therapeutic with an INN/USAN. No clinical-stage anti-CXCL14 antibody exists to match.
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseChemical/toxinMale and female
Model: Carbon tetrachloride induced acute liver injury, steatosis and acute liver failure
Anti-CXCL14 antibody treatment reduced the severity of carbon tetrachloride induced liver injury, with significant reductions in hepatic necrosis area (p < 0.05), liver fat deposition (p < 0.01) and serum malondialdehyde (p < 0.05), and reduced mortality from carbon tetrachloride induced liver fail…
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
